AstraZeneca
Headquarters country
United Kingdom
Registry sponsor category
Industry
- Other names
- AstraZeneca
- Company name
- AstraZeneca
- Organisation type
- Industry
- Registered legal name
- ASTRAZENECA PLC
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0000901832
- Legal Entity Identifier (LEI)
- PY6ZZQWO2IZFZC3IOL08
Related records
Trials (4,795)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- "Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design
- "Me and My Heart" Study
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
- [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
- 10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
- 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
- 14729-D9831C00002- 1 Month Biopsy Study
- 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
- 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
- 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
- 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
- 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects
- 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
- 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period